Rational design, synthesis and biological evaluation of novel HIV-1 protease inhibitors containing 2-phenylacetamide derivatives as P 2 ligands with potent activity against DRV-Resistant HIV-1 variants
Bioorganic & Medicinal Chemistry Letters, ISSN: 0960-894X, Vol: 101, Page: 129651
2024
- 1Citations
- 1Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Article Description
A novel kind of potent HIV-1 protease inhibitors, containing diverse hydroxyphenylacetic acids as the P 2-ligands and 4-substituted phenyl sulfonamides as the P 2′ ligands, were designed, synthesized and evaluated in this work. Majority of the target compounds exhibited good to excellent activity against HIV-1 protease with IC 50 values below 200 nM. In particular, compound 18d with a 2-(3,4-dihydroxyphenyl) acetamide as the P 2 ligand and a 4- methoxybenzene sulfonamide P 2′ ligand exhibited inhibitory activity IC 50 value of 0.54 nM, which was better than that of the positive control darunavir (DRV). More importantly, no significant decline of the potency against HIV-1 DRV R S (DRV-resistant mutation) and HIV-1NL4_3 variant (wild type) for 18d was detected. The molecular docking study of 18d with HIV-1 protease (PDB-ID: 1T3R, www.rcsb.org ) revealed possible binding mode with the HIV-1 protease. These results suggested the validity of introducing phenol-derived moieties into the P 2 ligand and deserve further optimization which was of great value for future discovery of novel HIV-1 protease.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0960894X24000532; http://dx.doi.org/10.1016/j.bmcl.2024.129651; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85185595569&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/38342391; https://linkinghub.elsevier.com/retrieve/pii/S0960894X24000532; https://dx.doi.org/10.1016/j.bmcl.2024.129651
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know